OncoMatch/Clinical Trials/NCT05145660
Optimization of Cervical Nodal CTV for Early and Medium Stage NPC
Is NCT05145660 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Chemotherapy for nasopharyngeal carcinoma.
Treatment: Chemotherapy — Current radiotherapy guidelines and consensus statements uniformly recommend elective region irradiation (ERI) as the standard strategy for nasopharyngeal carcinoma (NPC). However, given the scarcity of skip-metastasis, the improved assessment accuracy of nodal involvement, and the striking advancements in chemotherapy for NPC, a one-fits-all delineation scheme for clinical target volumes for the nodal region (CTVn) may not be appropriate anymore, and modifications of the CTVn delineation strategy may be warranted. Involved site irradiation (ISI) covering merely the initially involved nodal site and potential extranodal extension has been confirmed to be as effective as ERI with decreased radiation-related toxicities in some malignancies, but has not yet been investigated in NPC. This study aims to compare the regional control, survival outcomes, radiation-related toxicities, and quality of life (QoL) of ISI with conventional ERI in NPC patients with a limited nodal burden.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage I, II, III
Lab requirements
Blood counts
hemoglobin ≥ 120 g/l, wbcs ≥ 4 × 109 /l, platelets ≥ 100 × 109 /l
Kidney function
kidney function-related indicators within 1.25*the normal upper limit
Liver function
liver function-related indicators within 1.25*the normal upper limit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify